Stock of the Biopharmaceutical company  Supernus Pharmaceuticals Inc ( SUPN ) moving higher with a gain of more than 36 % and trading above $14.50 with strong volumes. A strong up move along with volumes might be seen as a breakout and stock might cross its 52 week high $15.20. We recommend a buy side trading approach for short term with a 52 week high break out target in the stock. Although there was no official announcements from the company regarding any development.

Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus’s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.